What is Qnovia?
Qnovia, Inc. is dedicated to the development and commercialization of innovative inhalation device technologies designed to improve patient treatment efficacy. The company's core focus lies in its drug delivery platforms, which hold substantial potential for applications in managing conditions such as Asthma and COPD, as well as in vaccine delivery and pain management. Qnovia is strategically positioned to leverage its technology for both generic and select investigational new drugs, addressing critical needs within the pharmaceutical landscape.
How much funding has Qnovia raised?
Qnovia has raised a total of $33M across 2 funding rounds:
Series A
$17M
Series B
$16M
Series A (2022): $17M with participation from Evolution VC Partners, Gaingels, Vice Ventures, TL Capital Holdings, Blue Ledge Capital, and DG Ventures
Series B (2024): $16M led by Gaingels, Vice Ventures, Blue Ledge Capital, and Evolution VC Partners
Key Investors in Qnovia
Gaingels
Gaingels is a leading investment syndicate supporting the LGBTQ community and allies, investing in companies with LGBT founders and inclusive teams across various sectors from Seed to Growth stages.
Vice Ventures
Vice Ventures is a seed-stage venture capital fund that focuses on investing in companies operating in industries often viewed negatively, aiming to conquer stigmas while striving for superior returns.
Blue Ledge Capital
Blue Ledge Capital is a non-traditional venture capital firm that focuses on capitalizing businesses committed to building the future, operating on a low one-time syndication fee model.
What's next for Qnovia?
The substantial enterprise-level backing Qnovia has garnered, particularly the recent major strategic investment, positions the company for accelerated growth and market penetration. This infusion of capital is expected to fuel further research and development, scale manufacturing capabilities, and expand its commercial reach. Qnovia's focus on improving patient outcomes through advanced inhalation technology suggests a strategic trajectory aimed at capturing significant market share in respiratory care, vaccine delivery, and pain management sectors. The company's ability to attract significant investment indicates strong investor confidence in its technological innovation and market potential.
See full Qnovia company page
